Existing research data show that SGLT2 inhibitors have a significant effect on a variety of risk factors such AS hyperglycemia, hypertension, abnormal lipid metabolism, and obesity, as well as the functions of endothelial cells, macrophages, and smooth muscle cells, which are closely related to the occurrence and development of AS (23–25). This evidence concerns the gene SLC5A2 and Hypertension.